The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Stimulation of Lipogenesis by Pharmacological Activation of the Liver X Receptor Leads to Production of Large, Triglyceride-rich Very Low Density Lipoprotein Particles
Open accessAbstract
The oxysterol-activated liver X receptor (LXR) provides a link between sterol and fatty acid metabolism; activation of LXR induces transcription of lipogenic genes. This study shows that induction of the lipogenic genes Srebp-1c, Fas, and Acc1 upon administration of the synthetic LXR agonist T0901317 to C57BL/6J mice (10 mg/kg/day, 4 days) is associated with massive hepatic steatosis along the entire liver lobule and a 2.5-fold increase in very low density lipoprotein-triglyceride (VLDL-TG) secretion. The increased VLDL-TG secretion was fully accounted for by formation of larger (129 +/- 9 nm versus 94 +/- 12 nm, a 2.5-fold increase of particle volume) TG-rich particles. Stimulation of VLDL-TG secretion did not lead to elevated plasma TG levels in C57BL/6J mice, indicating efficient particle metabolism and clearance. However, T0901317 treatment did lead to severe hypertriglyceridemia in mouse models of defective TG-rich lipoprotein clearance, i.e. APOE*3-Leiden transgenic mice (3.2-fold increase) and apoE-/- LDLr-/- double knockouts (12-fold increase). Incubation of rat hepatoma McA-RH7777 cells with T0901317 also resulted in intracellular TG accumulation and enhanced TG secretion. We conclude that, in addition to raising high density lipoprotein cholesterol concentrations, pharmacological LXR activation in mice leads to development of hepatic steatosis and secretion of atherogenic, large TG-rich VLDL particles.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT
Lowry, O., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 317,331
A RAPID METHOD OF TOTAL LIPID EXTRACTION AND PURIFICATION
Bligh, E. G., & Dyer, W. J. (1959) · Canadian Journal of Biochemistry and Physiology · doi:10.1139/o59-099 · Cited by 54,751
Direct transesterification of all classes of lipids in a one-step reaction.
Lepage, G., & Roy, C. C. (1986) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38861-1 · Cited by 2,384
Repa, J. J., Liang, G., Ou, J., Bashmakov, Y., Lobaccaro, J.-M. A., Shimomura, I., Shan, B., Brown, M. S., Goldstein, J. L., & Mangelsdorf, D. J. (2000) · Genes & Development · doi:10.1101/gad.844900 · Cited by 1,692
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J., Kwiterovich, P., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,648
Role of LXRs in control of lipogenesis
Schultz, J. R., Tu, H., Luk, A., Repa, J. J., Medina, J. C., Li, L., Schwendner, S., Wang, S., Thoolen, M., Mangelsdorf, D. J., et al. (2000) · Genes & Development · doi:10.1101/gad.850400 · Cited by 1,499
Peet, D. J., Turley, S. D., Ma, W., Janowski, B. A., Lobaccaro, J.-M. A., Hammer, R. E., & Mangelsdorf, D. J. (1998) · Cell · doi:10.1016/s0092-8674(00)81432-4 · Cited by 1,436
Regulation of Absorption and ABC1-Mediated Efflux of Cholesterol by RXR Heterodimers
Repa, J. J., Turley, S. D., Lobaccaro, J.-M. A., Medina, J., Li, L., Lustig, K., Shan, B., Heyman, R. A., Dietschy, J. M., & Mangelsdorf, D. J. (2000) · Science · doi:10.1126/science.289.5484.1524 · Cited by 1,301
Activation of the Nuclear Receptor LXR by Oxysterols Defines a New Hormone Response Pathway
Lehmann, J. M., Kliewer, S. A., Moore, L. B., Smith-Oliver, T. A., Oliver, B. B., Su, J.-L., Sundseth, S. S., Winegar, D. A., Blanchard, D. E., Spencer, T. A., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3137 · Cited by 1,233
LXR, a nuclear receptor that defines a distinct retinoid response pathway.
Willy, P. J., Umesono, K., Ong, E. S., Evans, R. M., Heyman, R. A., & Mangelsdorf, D. J. (1995) · Genes & Development · doi:10.1101/gad.9.9.1033 · Cited by 1,123
Cited by
Nair, J. K., Willoughby, J. L. S., Chan, A., Charisse, K., Alam, M. R., Wang, Q., Hoekstra, M., Kandasamy, P., Kel’in, A. V., Milstein, S., et al. (2014) · Journal of the American Chemical Society · doi:10.1021/ja505986a · Cited by 1,141
STRUCTURE, FUNCTION, AND DIETARY REGULATION OF Δ6, Δ5, AND Δ9 DESATURASES
Nakamura, M. T., & Nara, T. Y. (2004) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.24.121803.063211 · Cited by 1,073
Transcriptional Regulation of Metabolism
Desvergne, B., Michalik, L., & Wahli, W. (2006) · Physiological Reviews · doi:10.1152/physrev.00025.2005 · Cited by 892
Iqbal, J., & Hussain, M. M. (2009) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90899.2008 · Cited by 811
Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)
MUSSO, G., GAMBINO, R., & CASSADER, M. (2009) · Progress in Lipid Research · doi:10.1016/j.plipres.2008.08.001 · Cited by 681
Metabolic-associated fatty liver disease and lipoprotein metabolism
Heeren, J., & Scheja, L. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101238 · Cited by 646
Hyperlipidemic Effects of Dietary Saturated Fats Mediated through PGC-1β Coactivation of SREBP
Lin, J., Yang, R., Tarr, P. T., Wu, P.-H., Handschin, C., Li, S., Yang, W., Pei, L., Uldry, M., Tontonoz, P., et al. (2005) · Cell · doi:10.1016/j.cell.2004.11.043 · Cited by 625
LXRS AND FXR: The Yin and Yang of Cholesterol and Fat Metabolism
Kalaany, N. Y., & Mangelsdorf, D. J. (2006) · Annual Review of Physiology · doi:10.1146/annurev.physiol.68.033104.152158 · Cited by 615
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Sanders, F. W. B., & Griffin, J. L. (2016) · Biological Reviews · doi:10.1111/brv.12178 · Cited by 539
The Liver X Receptor (LXR) and Hepatic Lipogenesis
Cha, J.-Y., & Repa, J. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m605023200 · Cited by 470
Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance
Choi, S. H., & Ginsberg, H. N. (2011) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2011.04.007 · Cited by 418
Liver X receptor in cholesterol metabolism
Zhao, C., & Dahlman-Wright, K. (2010) · Journal of Endocrinology · doi:10.1677/joe-09-0271 · Cited by 418
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol Balance
Warrier, M., Shih, D. M., Burrows, A. C., Ferguson, D., Gromovsky, A. D., Brown, A. L., Marshall, S., McDaniel, A., Schugar, R. C., Wang, Z., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2014.12.036 · Cited by 414
“When treated with the LXR agonist T0901317, both control ASO- and FMO3 ASO-treated mice exhibited mild hypercholesterolemia, with the majority of the cholesterol elevation seen in large HDL particles (data not shown), as has been previously described (Grefhorst et al., 2002).”
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Costet, P., Cariou, B., Lambert, G., Lalanne, F., Lardeux, B., Jarnoux, A.-L., Grefhorst, A., Staels, B., & Krempf, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508582200 · Cited by 304
Self-citationMulvihill, E. E., Allister, E. M., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Markle, J. M., Hegele, R. A., & Huff, M. W. (2009) · Diabetes · doi:10.2337/db09-0634 · Cited by 297
Sugden, M. C., & Holness, M. J. (2006) · Archives of Physiology and Biochemistry · doi:10.1080/13813450600935263 · Cited by 284
Smet, E. D., Mensink, R. P., & Plat, J. (2012) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201100722 · Cited by 275
Metabolic Enzymes Enjoying New Partnerships as RNA-Binding Proteins
Castello, A., Hentze, M. W., & Preiss, T. (2015) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2015.09.012 · Cited by 274
Hepatic triacylglycerol accumulation and insulin resistance
Nagle, C. A., Klett, E. L., & Coleman, R. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800053-jlr200 · Cited by 272
“In mice, oral LXR agonists result in enhanced hepatic FA synthesis, hepatic steatosis, and hypertriglyceridemia, all mediated by increased expression of SREBP-1c (4).”
BackgroundInfluentialHepatic Steatosis: A Mediator of the Metabolic Syndrome. Lessons From Animal Models
den Boer, M., Voshol, P. J., Kuipers, F., Havekes, L. M., & Romijn, J. A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000116217.57583.6e · Cited by 260
Self-citationATP-Binding Cassette Transporters, Atherosclerosis, and Inflammation
Westerterp, M., Bochem, A. E., Yvan-Charvet, L., Murphy, A. J., Wang, N., & Tall, A. R. (2014) · Circulation Research · doi:10.1161/circresaha.114.300738 · Cited by 257
Seo, J. B., Moon, H. M., Kim, W. S., Lee, Y. S., Jeong, H. W., Yoo, E. J., Ham, J., Kang, H., Park, M.-G., Steffensen, K. R., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3430-3444.2004 · Cited by 250
Fitz, N. F., Cronican, A., Pham, T., Fogg, A., Fauq, A. H., Chapman, R., Lefterov, I., & Koldamova, R. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1051-10.2010 · Cited by 175
Novel HDL-directed pharmacotherapeutic strategies
deGoma, E. M., & Rader, D. J. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2010.200 · Cited by 149
Liver X receptors (LXR) as therapeutic targets in dyslipidemia
Bełtowski, J. (2008) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2008.00062.x · Cited by 132
Signalling mechanisms linking hepatic glucose and lipid metabolism
Weickert, M. O., & Pfeiffer, A. F. H. (2006) · Diabetologia · doi:10.1007/s00125-006-0295-3 · Cited by 127
“However, in mice, pharmacological LXR activation not only improves glucose metabolism, but also activates SREBP-1c and FASN, thereby causing severe hepatic steatosis [44], which, in turn, may have unfavourable effects on insulin sensitivity.”
BackgroundBrunham, L. R., Kruit, J. K., Pape, T. D., Parks, J. S., Kuipers, F., & Hayden, M. R. (2006) · Circulation Research · doi:10.1161/01.res.0000244014.19589.8e · Cited by 118
Self-citationRegulation of the angiopoietin-like protein 3 gene by LXR
Kaplan, R., Zhang, T., Hernandez, M., Gan, F. X., Wright, S. D., Waters, M. G., & Cai, T.-Q. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200367-jlr200 · Cited by 106
Mitochondrial Activity and Dynamics Changes Regarding Metabolism in Ageing and Obesity
López-Lluch, G. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.12.005 · Cited by 103
“sterol regulatory element binding protein 1c (SREBP-1c) (Grefhorst et al., 2002; Repa et al., 2000).”
BackgroundJohnson, S. M., Bao, H., McMahon, C. E., Chen, Y., Burr, S. D., Anderson, A. M., Madeyski-Bengtson, K., Lindén, D., Han, X., & Liu, J. (2024) · Nature Communications · doi:10.1038/s41467-024-49224-x · Cited by 100
Apolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities
Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91
The LXR–Idol Axis Differentially Regulates Plasma LDL Levels in Primates and Mice
Hong, C., Marshall, S. M., McDaniel, A. L., Graham, M., Layne, J. D., Cai, L., Scotti, E., Boyadjian, R., Kim, J., Chamberlain, B. T., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.001 · Cited by 87
Jin, S. H., Yang, J. H., Shin, B. Y., Seo, K., Shin, S. M., Cho, I. J., & Ki, S. H. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.04.023 · Cited by 83
ApoA5 lowers triglyceride levels via suppression of ANGPTL3/8-mediated LPL inhibition
Chen, Y. Q., Pottanat, T. G., Zhen, E. Y., Siegel, R. W., Ehsani, M., Qian, Y.-W., & Konrad, R. J. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100068 · Cited by 82
Töröcsik, D., Szanto, A., & Nagy, L. (2009) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2009.02.002 · Cited by 82
The hepatokine Tsukushi is released in response to NAFLD and impacts cholesterol homeostasis
Mouchiroud, M., Camiré, É., Aldow, M., Caron, A., Jubinville, É., Turcotte, L., Kaci, I., Beaulieu, M.-J., Roy, C., Labbé, S. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.129492 · Cited by 57
Zafar, H., Ain, N. U., Alshammari, A., Alghamdi, S., Raja, H., Ali, A., Siddique, A., Tahir, S. D., Akbar, S., Arif, M., et al. (2022) · Nutrients · doi:10.3390/nu14081654 · Cited by 41
Peng, D., Hiipakka, R. A., Xie, J., Dai, Q., Kokontis, J. M., Reardon, C. A., Getz, G. S., & Liao, S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01202.x · Cited by 39
Liu, Y., Han, X., Bian, Z., Peng, Y., You, Z., Wang, Q., Chen, X., Qiu, D., & Ma, X. (2012) · Digestive Diseases and Sciences · doi:10.1007/s10620-011-1902-9 · Cited by 35
Jan, A., Karasinska, J. M., Kang, M. H., de Haan, W., Ruddle, P., Kaur, A., Connolly, C., Leavitt, B. R., Sorensen, P. H., & Hayden, M. R. (2015) · Neuroscience Letters · doi:10.1016/j.neulet.2015.05.007 · Cited by 28
Parameter adaptations during phenotype transitions in progressive diseases
Tiemann, C. A., Vanlier, J., Hilbers, P. A., & van Riel, N. A. (2011) · BMC Systems Biology · doi:10.1186/1752-0509-5-174 · Cited by 22
“This flux prediction was not directly measured, but is in good agreement with gene expression data showing increased hepatic levels of the VLDL and LDL receptor [29].”
BackgroundMethodResultInfluential
Metadata
- Authors
- Grefhorst, A., Elzinga, B. M., Voshol, P. J., Plo¨sch, T., Kok, T., Bloks, V. W., van der Sluijs, F. H., Havekes, L. M., Romijn, J. A., Verkade, H. J., & Kuipers, F.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 277
- Issue
- 37
- Pages
- 34182-34190
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2119343066
- Cited by
- 498
- References
- 49
- FWCI
- 17.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.